Journal
MOLECULAR ONCOLOGY
Volume 10, Issue 8, Pages 1305-1316Publisher
WILEY
DOI: 10.1016/j.molonc.2016.07.001
Keywords
Pancreatic cancer; Biomarker signatures; Early detection; Antibody microarrays; Recombinant antibodies
Categories
Funding
- VINNOVA [20011-03926]
- CREATE Health Translational Cancer Center
- Lund University Faculty of Engineering
- EU [241481 AFFINOMICS]
- BioCARE [20141023-107717]
- Invest in Skane
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors. (C) 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available